• FDA expands Tecentriq approval for metastatic lung cancer

    1 month ago - By Healio

    The FDA expanded the approval of atezolizumab to include first-line monotherapy of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression.
    The approval applies to use of the atezolizumab by patients who have no EGFR or anaplastic lymphoma kinase genomic tumor aberrations.
    This is the fourth indication in metastatic NSCLC and fifth overall in lung cancer for atezolizumab, a monoclonal antibody designed to bind with PD-L1.
    “We are pleased to offer people with certain types of lung cancer a new chemotherapy-free option that can
    Read more ...